Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer
Abstract
Castration-resistant prostate cancer is characterized by loss of the androgen inactivation enzyme HSD17B2, emphasizing the importance of intratumoral androgens in tumor progression. Inactive isoforms generated by alternative splicing destabilize the wild-type enzyme, adding steroidogenesis to other prostate cancer drivers that undergo oncogenic splicing, highlighting aberrant splicing as a therapeutic target.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 15, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-3410
Entities
People
- Elahe A. Mostaghel
Organizations
- National Cancer Institute
- United States Department of Defense
- VA Puget Sound Health Care System